[Adolescents with concurrent ADHD and substance use disorder; international consensus].
Jongeren met een stoornis in het gebruik van middelen en ADHD: internationale consensus.
Journal
Tijdschrift voor psychiatrie
ISSN: 0303-7339
Titre abrégé: Tijdschr Psychiatr
Pays: Netherlands
ID NLM: 0423731
Informations de publication
Date de publication:
2021
2021
Historique:
entrez:
3
1
2022
pubmed:
4
1
2022
medline:
5
1
2022
Statut:
ppublish
Résumé
Substance use disorder (SUD) is common among youths with attention-deficit/hyperactivity disorder (ADHD). Co-morbid ADHD and SUD in youths complicates screening, diagnosis, and treatment of both disorders and is associated with worse treatment prognosis. Limited research in youths with SUD and co-morbid ADHD provides insufficient basis for firm recommendations. To offer clinicians some guidance on this topic, we present the results of an international consensus procedure. To summarize an international consensus on diagnosis and treatment of young people with comorbid ADHD and SUD. In a modified Delphi-study, a multidisciplinary, international group of 55 experts strived to reach consensus on 37 recommendations. Consensus was reached on 36 recommendations. Routine screening of ADHD and/or SUD is important. For the treatment of co-morbid SUD and ADHD in youths, both psychosocial and pharmacological treatment should be considered. Psychosocial treatment should preferably consist of psychoeducation, motivational interviewing (MI), and cognitive behavioral therapy (CBT) focused on SUD or both disorders. Long-acting stimulants are recommended as first choice pharmacotherapy, preferably embedded in psychosocial treatment. Experts did not agree on the precondition that patients need to be abstinent before starting stimulant treatment. Clinicians and youths with co-morbid SUD and ADHD can use this international consensus to choose the best possible treatment.
Sections du résumé
BACKGROUND
BACKGROUND
Substance use disorder (SUD) is common among youths with attention-deficit/hyperactivity disorder (ADHD). Co-morbid ADHD and SUD in youths complicates screening, diagnosis, and treatment of both disorders and is associated with worse treatment prognosis. Limited research in youths with SUD and co-morbid ADHD provides insufficient basis for firm recommendations. To offer clinicians some guidance on this topic, we present the results of an international consensus procedure.
AIM
OBJECTIVE
To summarize an international consensus on diagnosis and treatment of young people with comorbid ADHD and SUD.
METHOD
METHODS
In a modified Delphi-study, a multidisciplinary, international group of 55 experts strived to reach consensus on 37 recommendations.
RESULTS
RESULTS
Consensus was reached on 36 recommendations. Routine screening of ADHD and/or SUD is important. For the treatment of co-morbid SUD and ADHD in youths, both psychosocial and pharmacological treatment should be considered. Psychosocial treatment should preferably consist of psychoeducation, motivational interviewing (MI), and cognitive behavioral therapy (CBT) focused on SUD or both disorders. Long-acting stimulants are recommended as first choice pharmacotherapy, preferably embedded in psychosocial treatment. Experts did not agree on the precondition that patients need to be abstinent before starting stimulant treatment.
CONCLUSION
CONCLUSIONS
Clinicians and youths with co-morbid SUD and ADHD can use this international consensus to choose the best possible treatment.
Substances chimiques
Central Nervous System Stimulants
0
Types de publication
Journal Article
Langues
dut
Sous-ensembles de citation
IM